Swedish Orphan AB

27 articles about Swedish Orphan AB

• First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout

  9/23/2020

  Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical programme of SEL-212 for chronic refractory gout, with the randomisation of the first patient in the study.

• First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

  9/23/2020

  Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.

• Actress Vanessa Lachey Joins Forces with Sobi to Raise Awareness of Severe RSV Disease and Steps Parents Can Take to Prevent It

  10/1/2019

  Sobi announced that actress/TV personality Vanessa Lachey is partnering with Sobi to raise awareness of respiratory syncytial virus

• Invitation to Sobi Capital Markets Day 14 May 2019

  2/21/2019

  Save the date for Swedish Orphan Biovitrum AB Capital Markets Day on 14 May 2019.

• Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune

  7/20/2018

  Swedish Orphan AB, an international biopharmaceutical company dedicated to rare diseases, and NovImmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis, developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.

• Henrik Stenqvist is Joining Sobi as New Chief Financial Officer

  2/26/2018

  Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring

• Kineret® Receives a Positive Opinion from CHMP for the Treatment of Still's Disease

  2/23/2018

  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for anakinra for the treatment of Still's disease.

• Sobi - First Patient Randomised in a Phase III Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease

  11/16/2017

  The purpose of the study is to assess the efficacy and to evaluate the safety of anakinra in patients with newly diagnosed Still's disease, including SJIA and AOSD.

• Sobi: The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta

  10/27/2017

  The study is designed to investigate the immune tolerance induction potential of Elocta in patients with hemophilia A who have developed inhibitors which have failed to be resolved with other therapies.

• Sobi: Alprolix Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B

  10/25/2017

  Sobi today annouced that the SFDA in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the treatment of haemophilia B.

• Sobi Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel

  10/24/2017

  Swedish Orphan AB today announces the establishment of a new leadership structure; Executive Committee, to replace the Executive Leadership Team in its current form.

• Swedish Orphan AB - Elocta Approved In The Kingdom Of Saudi Arabia For The Treatment Of Haemophilia A

  5/18/2017

• Swedish Orphan AB - FDA Approves In-Use Storage At Room Temperature For Orfadin Capsules

  3/7/2017

• Swedish Orphan AB Publishes Its Report For The Fourth Quarter And Full Year 2014

  2/19/2015

• Auxilium Pharmaceuticals Release: Swedish Orphan AB Files For EU Approval Of Xiapex For Peyronies Disease

  6/25/2014

• Biogen Idec, Inc. (Massachusetts) and Swedish Orphan Biovitrum Present New Data From the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE™

  7/8/2013

• Swedish Orphan Biovitrum Gets FDA Approval to Manufacture Substance for Kineret® With Partner Boehringer Ingelheim Corporation

  6/11/2013

• Swedish Orphan Biovitrum Appoints Mats-Olof Wallin as Permanent Chief Financial Officer

  5/17/2013

• Swedish Orphan Biovitrum Appoints Mats-Olof Wallin as Interim Chief Financial Officer

  4/8/2013

• Swedish Orphan Biovitrum Publishes Annual Report

  4/5/2013